|
|
|
|
| LEADER |
03688 am a22005173u 4500 |
| 001 |
73631 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Feldser, David M.
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
| 100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a Feldser, David M.
|e contributor
|
| 100 |
1 |
0 |
|a Kostova, Kamena K.
|e contributor
|
| 100 |
1 |
0 |
|a Winslow, Monte Meier
|e contributor
|
| 100 |
1 |
0 |
|a Taylor, Sarah E.
|e contributor
|
| 100 |
1 |
0 |
|a Cashman, Chris
|e contributor
|
| 100 |
1 |
0 |
|a Whittaker, Charles A.
|e contributor
|
| 100 |
1 |
0 |
|a Sanchez-Rivera, Francisco J.
|e contributor
|
| 100 |
1 |
0 |
|a Resnick, Rebecca
|e contributor
|
| 100 |
1 |
0 |
|a Hemann, Michael
|e contributor
|
| 100 |
1 |
0 |
|a Bronson, Roderick T.
|e contributor
|
| 100 |
1 |
0 |
|a Jacks, Tyler E.
|e contributor
|
| 700 |
1 |
0 |
|a Kostova, Kamena K.
|e author
|
| 700 |
1 |
0 |
|a Winslow, Monte Meier
|e author
|
| 700 |
1 |
0 |
|a Taylor, Sarah E.
|e author
|
| 700 |
1 |
0 |
|a Cashman, Chris
|e author
|
| 700 |
1 |
0 |
|a Whittaker, Charles A.
|e author
|
| 700 |
1 |
0 |
|a Resnick, Rebecca
|e author
|
| 700 |
1 |
0 |
|a Bronson, Roderick T.
|e author
|
| 700 |
1 |
0 |
|a Hemann, Michael
|e author
|
| 700 |
1 |
0 |
|a Sanchez-Rivera, Francisco Jav
|e author
|
| 700 |
1 |
0 |
|a Jacks, Tyler E
|e author
|
| 245 |
0 |
0 |
|a Stage-specific sensitivity to p53 restoration during lung cancer progression
|
| 260 |
|
|
|b Nature Publishing Group,
|c 2012-10-04T20:33:19Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/73631
|
| 520 |
|
|
|a 2011 May 25
|
| 520 |
|
|
|a Tumorigenesis is a multistep process that results from the sequential accumulation of mutations in key oncogene and tumour suppressor pathways. Personalized cancer therapy that is based on targeting these underlying genetic abnormalities presupposes that sustained inactivation of tumour suppressors and activation of oncogenes is essential in advanced cancers. Mutations in the p53 tumour-suppressor pathway are common in human cancer and significant efforts towards pharmaceutical reactivation of defective p53 pathways are underway1, 2, 3. Here we show that restoration of p53 in established murine lung tumours leads to significant but incomplete tumour cell loss specifically in malignant adenocarcinomas, but not in adenomas. We define amplification of MAPK signalling as a critical determinant of malignant progression and also a stimulator of Arf tumour-suppressor expression. The response to p53 restoration in this context is critically dependent on the expression of Arf. We propose that p53 not only limits malignant progression by suppressing the acquisition of alterations that lead to tumour progression, but also, in the context of p53 restoration, responds to increased oncogenic signalling to mediate tumour regression. Our observations also underscore that the p53 pathway is not engaged by low levels of oncogene activity that are sufficient for early stages of lung tumour development. These data suggest that restoration of pathways important in tumour progression, as opposed to initiation, may lead to incomplete tumour regression due to the stage-heterogeneity of tumour cell populations.
|
| 520 |
|
|
|a National Cancer Institute (U.S.) (Cancer Center Support Grant P30-CA14051)
|
| 520 |
|
|
|a American Cancer Society (New England Area Fellow)
|
| 520 |
|
|
|a Leukemia & Lymphoma Society of America (Fellow)
|
| 520 |
|
|
|a Massachusetts Institute of Technology. Undergraduate Research Program (John Reed Fund)
|
| 520 |
|
|
|a Damon Runyon Cancer Research Foundation (Merck Fellow)
|
| 520 |
|
|
|a Genentech, Inc. (Postdoctoral Fellow)
|
| 520 |
|
|
|a Howard Hughes Medical Institute
|
| 546 |
|
|
|a en_US
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Nature
|
